Skip to main content

FOLD

Stock

FOLD

Stock
Health Care
Biotechnology

Performance overview

FOLD Price
Price Chart

Forward-looking statistics

Beta
0.97
Risk
37.25%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees701
Market cap$3.0B

Fundamentals

Enterprise value$2.0B
Revenue$543.1M
Revenue per employee—
Profit margin-5.41%
Debt to equity229.11

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.09
Dividend per share—
Revenue per share$1.78
Avg trading volume (30 day)$31M
Avg trading volume (10 day)$38M
Put-call ratio—

Macro factor sensitivity

Growth+0.2
Credit+6.4
Liquidity+2.5
Inflation-5.2
Commodities-1.9
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio38.13
Price to sales3.46
P/E Ratio38.13
Enterprise Value to Revenue3.60
Price to book9.70

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

New Strong Sell Stocks for June 3rd

FOLD, BRCC and VLVLY have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2025.

Zacks Investment Research (June 3, 2025)
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.

Benzinga (December 13, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free